Clinical trials: Chronic Central Serous Chorioretinopathy, active
Central Serous Chorioretinopathy (CSC)
Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
Dysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous…
- Trial name
- NCT07681167
- Testing
- Faricimab
- Volunteers
- 50 people
- Sponsor
- Singapore National Eye Centre